Method for preparing cattle viral diarrhoea vaccine. RU patent 2502522.
 Strain of bacteriophage escherichia coli ecd4, having lytic activity in respect to bacteria escherichia coli of serotype o104:h4 / 2496874Invention relates to a strain of the bacteriophage Escherichia coli ECD4. The strain of the bacteriophage Escherichia coli ECD4 is isolated from faeces of broiler chickens on the culture of the bacteria of the strain Escherichia coli O104.H4 RK1No.112027 and is deposited in the State Collection of Pathogenic Microorganisms and Cell Cultures "GKPM-Obolensk" under the number Ph63. The proposed strain of the bacteriophage has lytic activity in respect to the bacteria of the strain Escherichia coli O104:H4 RKINo.112027, lyses Escherichia of the serotype 0157:H7, does not suppress growth of cells Escherichia coli M-17, has lytic activity in respect to several other clinically significant serotypes of Escherichia, and also to several types of Shigella. The strain of the bacteriophage Escherichia coli ECD4 propagates on the laboratory non-pathogenic strain Escherichia coli K-12 C600F. |
 Strain of enterovirus coxsackie b6 selectively infecting and lysing tumorous human cells in vitro / 2496873Described strain is produced by performance of a series of adaptation passages of a parent strain of the virus ZhEV-15 Coxsackie B6 on the culture of cells HEK293 highly sensitive to this virus and the neoplastic cell line C33A (HPV-negative carcinoma of human uterine neck), with production of a new strain ZhEV-15L of the virus Coxsackie B6. The strain selectively infects and lyses tumorous human cells and has a fragment of a genome sequence represented in the dwg. 2, being its marker criterion. The strain is deposited in the State Collection of the Federal Service for Oversight of Consumer Protection and Welfare of agents of viral infections and rickettsial diseases of the Federal Budget Institution of Science State Science Centre of Virusology and Biotechnology "Vector" under the registration number V-576. |
|
Strain of flu virus a/common gull/altai/804/2011/h16no-subtype for production of antigene-containing preparation, polyclonal serum and application as control reference-sample when assessing specificity of test-systems based on polymerase chain reaction / 2496872 Invention relates to the field of microbiology and relates to the strain of flu virus of H16N3-subtype. The strain of bird flu virus A/common gull/Altai/804/2011/H16N3-subtype is described, deposited in the State Collection of Viral Infectons and Rickettsial diseases of the Federal Budget Institution of Science State Science Centre of Virusology and Biotechnology "Vector" under the registration number V-583. The strain was isolated from a common gull (Larus canus). The strain may be used to produce a polyclonal serum to determine affinity of the flu virus to H16-subtype, and also may be used as a control reference sample when assessing specificity of test systems on the basis of PCR. |
 Genes coding major capsid protein l1 of human papilloma virus, and using them / 2494106Invention refers to biotechnology and virology. The present invention discloses a codon-optimised gene coding the major capsid protein L1 of human papilloma virus which is able for effective expression of the major capsid protein L1 of human papilloma virus after transducing into a yeast cell. What is also described is an immunogenic macromolecule which is preferentially formed by the expression of the above codon-optimising gene coding the major capsid protein L1 of human papilloma virus in the yeast cell. What is also disclosed is using the above immunogenic macromolecule and composition containing the above immunogenic macromolecule. |
 Methods and compositions for immunisation of pigs against porcine circovirus / 2493254Nucleic acids are described, which code genomes of two new strains of porcine circovirus of type 2B. These two new strains of porcine circovirus may be used to produce a vaccine or an immunogenic composition for immunisation of pigs against porcine multisystemic wasting syndrome (PMWS). |
 Attenuated strain "kem-7" of fowlpox virus for manufacturing of preparations of specific prevention and diagnostics of fowl pox / 2493253New strain "KEM-7" of the fowlpox virus is produced by multiple passages of mother virus on developing chicken embryos. The strain is deposited into the collection of FSBI VGNKI under the registration number (reference) - strain "KEM-7" - DEP of fowlpox virus. The strain is genetically authentic by the sequence of nucleotides of the gene 241ext. It is adapted to the organism of developing chicken embryos. It is immunogenic, moderately reactogenic and harmless for birds in case of an intradermal injection. It preserves the attenuated phenotype during passages both in the cultivation system and on a naturally receptive bird. |
|
Rubella virus strain "orlov" (u) for obtaining medicinal immuno-biological preparations (mibp) / 2492235 Strain was deposited under number V-1 in the collection "SCPM-Obolensk". The strain may be used to produce monovalent rubella vaccine, associated combined vaccines comprising the vaccine strain of rubella virus, as well as for production of diagnostic products. |
 Cytomegalovirus vaccine and method for preparing it / 2491340Invention refers to vaccinology and cell biology. |
 Method of replication of influenza virus in culture / 2491339Invention relates to field of biotechnology and virology. Method of selecting human influenza virus for growing on tissue culture cells by method of limiting dilution cloning. Method includes dilution of influenza virus, its mixing with tripsin, contact with cells of tissue cultures, growing and harvesting of virus. Said stages are performed 2-3 times. Also described is method of obtaining vaccine against human influenza virus with application of claimed method of selecting influenza virus. |
|
Strain of virus of infectious anaemia of chickens no2722 in state virus collection for production of diagnosticums / 2489487 Strain is extracted from liver of spontaneously ill broiler chickens and is deposited in the State Virus Collection of the Virosology Institute named after D.I. Ivanovskiy under the number No. 2722. The strain relates to the family of Circoviridae, variety of Circovirus, has intense infectious and antigene activity. |
 Combined drug for treating bacterial infections and method of treating bacterial infections / 2502521Present group of inventions refers to medicine, namely therapy, and concerns treating bacterial infections. That is ensured by a combined drug containing an activated potentiated form of human gamma-interferon (IFN-γ) antibodies, an activated potentiated form of CD4 receptor antibodies and an activated potentiated form of histamine antibodies. |
 Combined drug for treating viral infections and method of treating viral infections / 2500422Present group of inventions refers to medicine, namely therapy, and concerns treating viral infections. That is ensured by administering a combined drug containing human activated potentiated gamma-interferon, CD4 receptor and histamine antibodies. |
 Using purine derivatives for preparing drug preparation / 2500400Invention refers to chemical-pharmaceutical industry, namely to using a purine derivatives for preparing drug preparations for treating chronic lymphocytic leukaemia and polycystic kidneys. |
 Antiviral composition solution and method for preparing it / 2499601Invention refers to an antiviral composition solution and a method for preparing it. The antiviral composition solution contains complex silver, glycine complex bound to silver, sodium glycinate and water in certain proportions. The method for preparing the above antiviral composition solution consists in electrolysis of the solution containing the glycine compounds and sodium glycinate to provides the electric conductivity of the solution; the electrolysis of the solution is conducted to achieve the silver concentration of 0.1-0.45 wt %. The electrolysis is followed by chemical oxidation of the prepared solution to improve its stability, and the precipitation is filtered. |
 Conjugates of gossypol and sodium-carboxymethyl cellulose, their production methods and antiviral agents on their basis / 2499002Invention refers to conjugate of gossypol with sodium-carboxymethyl cellulose with molecular mass of 780-180000 Da at the ratio of gossypol to sodium-carboxymethyl cellulose of (1-5):(99-95) wt % and content of low-molecular fraction with molecular mass of 780 to 1500 Da of up to 20% and high-molecular fraction with molecular mass of 1500 to 180000 Da of up to 80%, conjugate of gossypol with sodium-carboxymethyl cellulose with molecular mass of 780 to 1500 Da at the ratio of gossypol to sodium-carboxymethyl cellulose of (0.35-1.76):(99.65-98.24) wt %, and conjugate of gossypol with sodium-carboxymethyl cellulose with molecular mass of 1500 to 180000 Da at the ratio of gossypol to sodium-carboxymethyl cellulose of (0.65-3.23):(99.35-96.77) wt %, and their production methods. Besides, the invention refers to antiviral agents on the basis of the above conjugates and pharmaceutical compositions containing conjugates. |
 Antibodies to nkg2a and their applications / 2499001Invention proposes humanised anti-NKG2A antibody obtained from murine antibody Z270, which is characterised through amino-acid sequences of variable domains, and method of its obtainment. Besides, a pharmaceutical composition is described, which contains an antibody according to the invention, a treatment method and application of the antibody in production of a medicine to be injected into a patient who is a human being suffering the disorder chosen from cancer, virus disease, inflammatory disorder and autoimmune disorder. |
 Peptides with large number of bridge links, which are extracted from actinomadura namibiensis / 2498995Invention proposes compounds of labyrinthpeptins A1, A2, or A3 of formula (I) , where {A}, {B}, {C}, R1-R6, m and n have the values specified in the formula of the invention. Compounds are obtained at fermentation of Actinomadura namibiensis DSM 6313 strain under acceptable conditions in cultural environment till one or more compounds of formula (I) are formed. The invention proposes the deoxyribonucleic acid (DNA) coding preprolabyrinthpeptin A2, and the deoxyribonucleic acid (DNA) coding preprolabyrinthpeptin A1, as well as preprolabyrinthpeptins A1 and A2, and prolabyrinthpeptins A1 and A2. Labyrinthpeptins of formula (I) are used for therapy of infections caused by gram-positive bacteria, virus infections and/or neuropathic pain caused by inflammation. |
 Phenylaminopyrimidine compounds and uses thereof / 2498983Invention relates to novel phenylaminopyrimidine compounds of formula I, which are JAK kinase inhibitors. In particular, these compounds selectively act on JAK2 kinase. The compounds can be used to treat diseases such as immunological and inflammatory diseases; hyperproliferative diseases, myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases. In the compound of formula I , Q and Z are independently selected from N and CR1; R1 is independently selected from hydrogen, halogen, R2, OR2, OH, R4, OR4, CN, CF3, (CH2)nN(R2)2, where n equals 1,2 or 3, NO2, R2R4, NR2SO2R3, COR4, NR2COR3, CO2H, CO2R2, NR2COR4, R2CN, R2OH, R2OR3 and OR5R4; or two substitutes R1 together with carbon atoms with which they are bonded form an unsaturated 5- or 6-member heterocyclic ring containing 1-4 N atoms; R2 is C1-4alkyl; R4 is R2, C2-4alkenyl or phenyl; R4 is NH2, NHR2, N(R1)2, substituted or unsubstituted morpholine, CH2morpholine, substituted or unsubstituted thiomorpholine, substituted or unsubstituted thiomorpholino-1-oxide, substituted or unsubstituted thiomorpholino-1,1-dioxide, substituted or unsubstituted piperazinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted imidazolyl, substituted or tetrahydrofuranyl unsubstituted and substituted or unsubstituted tetrahydropyranyl; R5 is C2-4alkylene; R6-R9 are independently selected from H, RXCN, halogen, substituted or unsubstituted C1-4alkyl, OR1, CO2R1, N(R1)2, NO2 and CON(R1)2, wherein at least one of R6-R9 is RXCN; the rest of the values of the radicals are given in the claim. |
 Composition containing chitosan for ocular administration of vaccine (vaccines) to poultry / 2498818Group of inventions refers to veterinary science and aims at poultry vaccination by ocular administration. The declared composition contains one or more live attenuated viruses and chitosan. What is declared is using chitosan and one or more live attenuated viruses for preparing the composition for vaccination of avian species by ocular administration. What is also declared is using chitosan and one or more live attenuated viruses for preparing the vaccine composition for enhancing the cell-mediated immune response in poultry for separate or combined ocular administration. |
|
Combined preparation for influenza and acute respiratory viral infections / 2498797 Invention refers to a combined preparation for influenza and acute respiratory viral infections. As active substances, the declared preparation contains paracetamol 100-400 mg, phenylephrine hydrochloride 10 mg, pheniramine maleate 20 mg, and tilorone hydrochloride 20-60 mg. |
 Recombinant classical swine fever virus (csfv), which contains modified protein e2, and creation methods of above described recombinant csfv / 2501854Invention proposes recombinant classical swine fever virus (1111) that contains deletion of at least one amino-acid in TAVSPTTLR domain of protein E2, which corresponds to positions 829-837 of parent polyprotein CSFV, as well as the corresponding vaccine, kDNA molecule, a protection method of an animal against CSFV and a differentiation method of CSFV-infected animals. |
FIELD: medicine.
SUBSTANCE: invention refers to veterinary virology, microbiology and biotechnology and may be used in developing the agents for specific prevention, particularly for preparing cattle viral diarrhoea vaccine. To improve the quality of an end product by using an oxidant solution as an inactivating agent prepared by the electrolysis of sodium chloride solution, as well as to activate the method for preparing the cattle viral diarrhoea vaccine involving preparing a virus-containing material of the cattle viral diarrhoea vaccine strain, infecting a continuous cell culture with the virus-containing material, culturing the cattle viral diarrhoea virus, collecting a virus-containing fluid, inactivating and preparing the end product in the liquid form, with the cattle viral diarrhoea virus being inactivated by the oxidant solution prepared by electrolysis of 10.0-20.0% sodium chloride with the electrolysis carried out to pH 7.0-8.0, oxidant concentration 0.7-0.9% and redox potential +1000±50 mV; the processing is one-staged with the active chlorine content Cax=400-600 mg/l for 60-70 min with inactivating agent consumption 4.5-5.0 cm3 per 0.8-1.0 l of the virus-containing fluid.
EFFECT: higher quality of the end product.
3 ex
The invention refers to the veterinary Virology, Microbiology and biotechnology, and can be used when designing the specific prevention, and in particular for receiving the vaccine against viral diarrhea cattle.
A method of obtaining vaccines against viral diarrhea cattle which includes preparation material from the strain of the virus viral diarrhea Oregon, infection material culture of transplantable cells, culturing the virus viral diarrhoea, collection fluid, inactivation her with subsequent preparation of target product in liquid form (RF Patent №2372938, «bivalent Inactivated vaccine against viral diarrhea and adenovirus infection in cattle and a way of preventing viral diarrhea and adenovirus infection in cattle», publ. 20.11.2009, MKI 61 39/205).
The disadvantage of this technical solution is the use virus inactivation formalin, possessing a suspected carcinogen. It is known that with a slight excess of working concentration of formaldehyde causes a quick death cell cultures for the cultivation of viruses and suppression of infectious virus activity, that is often accompanied by a significant decline in potency. When preparing the vaccine is not excluded an opportunity of getting formaldehyde residues together with the vaccine organism animals, which is highly undesirable.
The task of the claimed technical solutions is to increase the quality of the target product due to the possibility of use as an inactivating agent solution of oxidants obtained by electrolysis of sodium chloride solution, and acceleration method.
The problem is solved by the method of producing vaccine against viral diarrhea cattle, including preparation material from the strain of the virus viral diarrhea cattle, infection material culture of transplantable cells, culturing the virus bovine viral diarrhea cattle, picking fluid, inactivation and subsequent preparation of the target product in liquid form to the fact that the inactivation of viral diarrhea virus cattle spend solution of oxidants, obtained by electrolysis of 10.0 to 20.0%solution of sodium chloride, and electrolysis lead to the achievement of the values of pH 7,0-8,0, the concentration of oxidants 0.7 to 0.9% and the redox potential of +1000ą50 mV, treatment is carried out in one stage, when the content of active chlorine Sakh=400-600 mg/l for 60 to 70 minutes at a flow rate of the inactivating means of 4.5-5.0 cm 3 0.8-1.0 l fluid.
The problem is solved by the way in which a vaccine against viral diarrhea cattle that, as the strain of the virus viral diarrhea cattle use strain Oregon or strain of the virus diarrhea cattle GKV 2336 of the family Flaviviridae kind Pestivirus.
Known strain of a virus diarrhea cattle Oregon (RF Patent №2372938, «bivalent Inactivated vaccine against viral diarrhea and adenovirus infection in cattle and a way of preventing viral diarrhea and adenovirus infection in cattle», publ. 20.11.2009, MKI 61 39/205).
Known strain of a virus diarrhea cattle GKV 2336, family Flaviviridae, genus Pestivirus (RF Patent №2395299, inactivated Vaccine combined against infectious rhinotracheitis, virus diarrhea, Rota, coronavirus disease and leptospirosis cattle, IPC 61 39/295, C12N 7/08, A61P 31/12, publ. 27.07.2010).
The invention is illustrated by the following examples.
Example 1. Prepare material from the strain Oregon viral diarrhea virus cattle, infect material culture of transplantable cells of coronary vessels calf «CSD», cultivate viral diarrhea virus cattle to achieve titer 6,0 lg ( 50/ml), collect fluid, inactivating solution of oxidants, obtained by electrolysis of 10.0%solution of sodium chloride, and electrolysis lead to the achievement of the values of pH 7.0, the concentration of oxidants 0,7% and the redox potential of +950 mW, the treatment is carried out in one stage, when the content of active chlorine Sakh=400 mg/l for 60 min at a rate of inactivating tools 4.5 cm 3 0.8 l fluid in the final concentration at temperature 37 C for 60 minutes at a pH of 7.2. Next target product is produced according to the known method. Received 1 vaccine, which has antigenic activity in the reaction of neutralization of 1:512, while in the known method antigenic activity amounted to 1:256.
The vaccine tested on antigenicity on laboratory animals. As a result of vaccine was and had a protective properties.
Example 2. Prepare material from the strain Oregon viral diarrhea virus cattle, infect material culture of transplantable cells of coronary vessels calf «CSD», cultivate viral diarrhea virus cattle to achieve titer of 6.5 lg ( 50/ml), collect fluid, inactivating solution of oxidants, obtained by electrolysis of 20.0%solution of sodium chloride, and electrolysis lead to the achievement of the values of pH to 8.0, the concentration of oxidants 0.9% and redox capacity +1050 mW, the treatment is carried out in one stage, when the content of active chlorine Sakh=600 mg/l for 70 minutes at a flow rate of the inactivating tools 5.0 cm on 1,0 l liquid at a temperature of 38 degrees Celsius for 60 minutes at pH 7.4. Next target product is produced according to the known method. Vaccinated 2, which has an antigenic activity in the reaction of neutralization of 1:256, while in the known method antigenic activity amounted to 1:256.
The vaccine tested on antigenicity on laboratory animals. As a result of vaccine was and had a protective properties.
Example 3. Cook the seeds from the strain of a virus diarrhea cattle GKV 2336, family Flaviviridae, genus Pestivirus, infect material culture of transplantable cells of coronary vessels calf «CSD», cultivate viral diarrhea virus cattle to achieve titer 6,0 lg ( 50/ml), collect fluid, inactivating solution of oxidants, obtained by electrolysis of 10.0%solution of sodium chloride, and electrolysis lead to the achievement of values of pH 7.0, the concentration of oxidants 0,7% and the redox potential of +950 mW, the treatment is carried out in one stage, when the content of active chlorine Sakh=400 mg/l for 60 min at a rate of inactivating tools 4.5 cm 3 0.8 l liquid at 37 C for 60 minutes at a pH of 7.2. Next target product is produced according to the known method. Vaccinated 3, which has an antigenic activity in the reaction of neutralization of 1:512, while in the known method antigenic activity amounted to 1:256.
The vaccine tested on antigenicity on laboratory animals. As a result of vaccine was and had a protective properties.
Example 4. Prepare material from the strain of a virus diarrhea cattle GKV 2336, family Flaviviridae, genus Pestivims, infect material culture of transplantable cells of coronary vessels calf «CSD», cultivate viral diarrhea virus cattle to achieve the title of 6.5 lg ( 50/ml), collect fluid, inactivating solution of oxidants, obtained by electrolysis of 20.0%-solution of sodium chloride, and electrolysis lead to the achievement of the values of pH to 8.0, the concentration of oxidants 0.9% and the redox potential of +1050 mW, the treatment is carried out in one stage, when the content of active chlorine Sakh=600 mg/l for 70 minutes at a flow rate of the inactivating tools 5.0 cm 3 1.0 l liquid at a temperature of 38 degrees Celsius for 60 minutes at pH 7.4. Next target product is produced according to the known method. Vaccinated 4 which has antigenic activity in the reaction of neutralization of 1:512, while in the known method antigenic activity amounted to 1:256.
The vaccine tested on antigenicity on laboratory animals. As a result of vaccine was and had a protective properties.
In addition, obtained according to the claimed method vaccine has a storage period up to 1 year.
The technical result achieved in the application of the invention is to increase the effectiveness of processing materials at a lower concentration inactivating products, reduction of exposure treatment with 60 to 70 minutes against 72 hours of a prototype; it is established that the solution of oxidants belongs to hazard class IV, concentrations does not cause toxic action on the cell culture of coronary vessels calf «CSD», used for cultivation and accumulation material decomposes quickly after exposure to the virus, thereby excluding hit in an organism of animals with , provides reduced costs of acquisition of preparation to 6 times and increase the safety of the maintenance staff, no harmful influence on environment. The vaccine has sufficient antigenic activity and has protective properties. Method of processing material proposed ensures the safety of products derived from farm animals (meat, milk).
1. The method of obtaining vaccines against viral diarrhea cattle, including the preparation of material from the strain of the virus viral diarrhea cattle, infection material culture of transplantable cells, culturing the virus viral diarrhea cattle, collection fluid, inactivation and subsequent preparation of the target product in liquid form, wherein the inactivation of the viral diarrhea virus cattle spend solution of oxidants, obtained by electrolysis of 10.0-20.0%-bysolution of sodium chloride, and electrolysis lead to the achievement of the values of pH 7,0-8,0, the concentration of oxidants 0.7 to 0.9% and the redox potential of +1000ą50 mV, treatment is carried out in one stage, when the content of active chlorine Sakh=400-600 mg/l for 60 to 70 minutes at a flow rate of the inactivating means of 4.5-5.0 cm 3 0.8-1.0 l fluid.
2. The method according to claim 1, characterized in that the strain of the virus viral diarrhea cattle use strain Oregon or strain of the virus diarrhea cattle GKV 2336 of the family Flaviviridae kind Pestivirus.